Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin<sup>®</sup> protein MP0250: a preclinical study.

导出 OA

翻译打印收藏纠错

作者： Luigia,Rao ^[1] ; Kim,De Veirman ^[2] ; Donato,Giannico ^[1] ; Ilaria,Saltarella ^[1] ; Vanessa,Desantis ^[1] ; Maria Antonia,Frassanito ^[1] ; Antonio Giovanni,Solimando ^[1] ; Domenico,Ribatti ^[3] ; Marcella,Prete ^[1] ; Andreas,Harstrick ^[4] ; Ulrike,Fiedler ^[4] ; Hendrik,De Raeve ^[5] ; Vito,Racanelli ^[1] ; Karin,Vanderkerken ^[2] ; Angelo,Vacca ^[1]

作者单位： Department of Biomedical Sciences and Human Oncology, Unit of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy. ^[1] Department of Hematology and Immunology, Myeloma Center Brussels, Vrije Universiteit Brussel, Brussels, Belgium. ^[2] Department of Basic Medical Sciences, Neurosciences, and Sensory Organs, Section of Human Anatomy and Histology, University of Bari Medical School, National Cancer Institute "Giovanni Paolo II", Bari, Italy. ^[3] Molecular Partners AG, Zürich-Schlieren, Switzerland. ^[4] Department of Pathology, UZ Brussel, Vrije Universiteit Brussel, Brussels, Belgium. ^[5]

关键词 DARPin angiogenesis dual inhibitor multiple myeloma syngeneic mouse model

DOI 10.18632/oncotarget.24351

PMID 29568363

发布时间 2019-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交